Cargando…
Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
Triple-negative breast cancer (TNBC) has the worst prognosis among all molecular types of breast cancer. Because of the strong immunogenicity of TNBC cells, programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors, two kinds of immune checkpoint blockade agents, might help improve the pr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086576/ https://www.ncbi.nlm.nih.gov/pubmed/35685994 http://dx.doi.org/10.21147/j.issn.1000-9604.2022.02.07 |
_version_ | 1784704034248065024 |
---|---|
author | Liang, Yuehua Liu, Xiaoran Li, Kun Li, Huiping |
author_facet | Liang, Yuehua Liu, Xiaoran Li, Kun Li, Huiping |
author_sort | Liang, Yuehua |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) has the worst prognosis among all molecular types of breast cancer. Because of the strong immunogenicity of TNBC cells, programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors, two kinds of immune checkpoint blockade agents, might help improve the prognosis of TNBC. However, how to better use PD-1/PD-L1 inhibitors and select patients who may benefit from treatment options remains controversial. This article summarizes published clinical studies in which PD-1/PD-L1 inhibitors were used in patients with advanced TNBC to explore how to maximize effectiveness of these medications. |
format | Online Article Text |
id | pubmed-9086576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-90865762022-06-08 Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer Liang, Yuehua Liu, Xiaoran Li, Kun Li, Huiping Chin J Cancer Res Review Article Triple-negative breast cancer (TNBC) has the worst prognosis among all molecular types of breast cancer. Because of the strong immunogenicity of TNBC cells, programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors, two kinds of immune checkpoint blockade agents, might help improve the prognosis of TNBC. However, how to better use PD-1/PD-L1 inhibitors and select patients who may benefit from treatment options remains controversial. This article summarizes published clinical studies in which PD-1/PD-L1 inhibitors were used in patients with advanced TNBC to explore how to maximize effectiveness of these medications. AME Publishing Company 2022-04-30 /pmc/articles/PMC9086576/ /pubmed/35685994 http://dx.doi.org/10.21147/j.issn.1000-9604.2022.02.07 Text en Copyright ©2022 Chinese Journal of Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Review Article Liang, Yuehua Liu, Xiaoran Li, Kun Li, Huiping Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer |
title | Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer |
title_full | Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer |
title_fullStr | Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer |
title_full_unstemmed | Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer |
title_short | Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer |
title_sort | current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086576/ https://www.ncbi.nlm.nih.gov/pubmed/35685994 http://dx.doi.org/10.21147/j.issn.1000-9604.2022.02.07 |
work_keys_str_mv | AT liangyuehua currentsituationofprogrammedcelldeathprotein1programmedcelldeathligand1inhibitorsinadvancedtriplenegativebreastcancer AT liuxiaoran currentsituationofprogrammedcelldeathprotein1programmedcelldeathligand1inhibitorsinadvancedtriplenegativebreastcancer AT likun currentsituationofprogrammedcelldeathprotein1programmedcelldeathligand1inhibitorsinadvancedtriplenegativebreastcancer AT lihuiping currentsituationofprogrammedcelldeathprotein1programmedcelldeathligand1inhibitorsinadvancedtriplenegativebreastcancer |